Evaluation of Referring HCPs' and Parents'/Carers' Understanding of Specific Risks Associated With Strimvelis Treatment
Phase of Trial: Phase IV
Latest Information Update: 14 Jan 2019
At a glance
- Drugs GSK 2696273 (Primary)
- Indications Adenosine deaminase deficiency
- Focus Therapeutic Use
- Sponsors Orchard Therapeutics
- 04 Jan 2019 Planned number of patients changed from 1 to 10.
- 04 Jan 2019 Status changed from not yet recruiting to recruiting.
- 22 Dec 2017 Planned initiation date changed from 15 Dec 2017 to 31 Jan 2018.